Cryovagotomy Diabetes Trial

Obesity Clinical Trial

Official title:

Effects of Vagus Nerve Cryoablation on Glycemic Control and Weight Loss in Obese Patients With Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04276051
• Other study ID #: IRB00109624
• Status: Completed
• Phase: N/A
• Start date: October 23, 2020
• Est. completion date: February 8, 2022

Study information

• Verified date: February 2023
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The pilot study will assess the feasibility and efficacy of cryoablation procedure to freeze the vagus nerve in obese patients with type 2 diabetes. Aim 1 will focus on changes in glycemic control. Aim 2 will evaluate differences in body weight and anthropometric measurements. This study will provide much needed data for a novel therapeutic intervention to manage obese patients with type 2 diabetes.

Description:

Obesity is a growing epidemic, currently affecting over 1/3 of the adult US population and is a well-established risk factor for the development of diabetes and cardiovascular disease. Given that the majority of patients with type 2 diabetes (T2D) are obese, weight loss is the cornerstone of treatment, and has been shown to decrease risk of long term complications, lead to improvements in A1c and lipid levels, as well as decreased need for medications and improvements in quality of life. Unfortunately, lifestyle intervention is often ineffective at achieving long-term sustainable, clinically significant weight loss. Bariatric surgery is a successful intervention, leading to 20-30% weight loss with remission of diabetes in 30-65% of patients 1-5 years post surgery. However, this invasive procedure is associated with high rates of short- and long-term complications, including need for reoperations, vitamin/mineral deficiencies, anemia, and osteoporosis. It is clear that the current management options for obese patients, including lifestyle changes, medications and surgery, are suboptimal and innovative strategies are necessary to optimize diabetes control and weight management.

Energy balance and glycemic control are mediated largely by the gut-brain axis, specifically the vagus nerve. The vagus nerve can stimulate or inhibit food intake depending on nutritional status. Vagal nerve signaling is disrupted in the setting of obesity and thought to contribute to overeating behaviors. Vagus nerve blockade has the potential to be a highly efficacious, minimally invasive intervention to address current obesity treatment limitations. Clinical studies evaluating the efficacy of an implantable electric vagus nerve blockade device found that subjects lost on average 8.8% of total body weight at 1 year; patients with T2D experienced improved glycemic control, with an average A1c improvement of 1.0% at 12 months. Unfortunately, nearly 40% of subjects experienced side effects related to the device. A recent pilot study from the researchers of this study reported weight loss efficacy of a minimally invasive computerized tomography (CT) guided cryoablation of the vagus nerve in obese, non-diabetic subjects. Patients lost 5.6% of total body weight and 22.7% excess body weight at 6 months with no significant side effects. The purpose of this current study is to evaluate the feasibility and efficacy of this procedure through a randomized control trial in obese patients with T2D. The researchers hypothesize that those patients undergoing the cryoablation procedure will experience improvement in glycemic control and enhanced weight loss at 6 months follow-up compared to the control group.

Participants will be randomized to receive either CT guided cryoablation of the vagus nerve plus lifestyle intervention or lifestyle intervention alone. The lifestyle intervention lasts for 26 weeks and participants will be followed for 12 months in total.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: February 8, 2022
• Est. primary completion date: February 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Males and females between the ages of 22-65

2. Diagnosis of type 2 diabetes mellitus (T2DM) for <10 years

3. HbA1c between =7.5% and =10.5%

4. Treatment with non-insulin antidiabetic medications with stable doses for at least 3 months, with failed prior attempts at dietary interventions to optimize diabetes control

5. BMI 30-40 kg/m^2

6. Willing to comply with study requirements

7. Documented negative pregnancy test in women of child bearing potential and use of an effective birth control method

8. Average score of =3 on questions 4, 8, 9, 13, and 14 from the Three Factor Eating Questionnaire

Exclusion Criteria:

1. Diagnosis of type 1 diabetes or history of diabetic ketoacidosis

2. Use of insulin therapy

3. Significant kidney disease (eGFR < 60 ml/min/1.73m^2)

4. Current drug or alcohol addiction

5. Thyroid disease unless underlying diagnosis is primary hypothyroidism on stable medications for >3 months with thyroid stimulating hormone (TSH) in reference range at time of screening visit

6. Systemic steroid use within 30 days prior to randomization

7. Use of prescription or over the counter weight loss medications within 6 months prior to randomization

8. Weight gain/loss >5% over the past 6 months

9. Previous GI surgery or abnormal GI anatomy which may limit technical feasibility of the procedure

10. Recent diagnosis of cardiovascular disease requiring percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within the past 6 months

11. Abnormal pathologies or conditions of the GI tract, including peptic ulcers, hiatal hernia, active gallbladder disease, pancreatitis, cirrhosis, inflammatory bowel disease, upper GI bleed within 6 months of randomization

12. Any condition or major illness that places the subject at undue risk by participating in the study

13. Psychiatric condition rendering the subject unable to understand the possible consequences of the study

14. Inability to provide informed consent

15. Female subjects who have been pregnant within 6 months or breast-feeding at time of enrollment into the study, or women who plan to become pregnant within the next 12 months

16. Diagnosis of anemia, red blood cell (RBC) transfusion in the preceding 3 months or expectation to receive transfusion within the next 12 months, or hemoglobinopathies that would affect HbA1c reliability

17. Active or recent infection

18. Immunosuppression

19. History of coagulopathy or high risk for development of deep vein thrombosis (including congestive heart failure, those who are non-ambulatory, active leukemia/lymphoma, prior thrombotic events, family history of thrombosis)

20. History of blood pressure instability (systolic BP =100 or =160 mmHg)

21. History of autonomic dysfunction, including amyloidosis, Parkinson's disease, autoimmune disease, spinal cord injury

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes Type 2
• Obesity

Intervention

Device:
• Cryoablation of the Vagus Nerve
The Visual ICE Cryoablation System is a mobile console system intended for cryoablative tissue destruction using a minimally invasive procedure. The Visual-ICE System uses high-pressure argon gas that circulates through closed-tip cryoablation needles to induce tissue freezing. Active tissue thawing is achieved by circulating helium gas through the needles or, alternatively, by the use of Galil Medical i-Thaw technology. The procedure will be done under CT guidance and involves a 4-5 mm scalpel incision followed by percutaneous probe placement about the posterior gastroesophageal junction (the location of the posterior vagal trunk). The probe will create a zone of decreased temperature (-20 to -40 degrees Celsius) involving the posterior vagal nerve fibers/plexus. The cryoablation process will include a 3-minute freeze, followed by a 1-minute thaw, and a second 3-minute freeze and 1 minute thaw.

Behavioral:
• Lifestyle Intervention
The lifestyle intervention structure will include three face-to-face counseling sessions at baseline, 3 and 6 months. Dietary counseling to follow a low carbohydrate diet will be provided by a registered dietitian. Focus will be on increasing fruits and vegetables and decreasing refined sugars and processed foods. It will also include motivational interviewing, goal setting and nutrition education. In addition, subjects will be encouraged by exercise physiologist to slowly increase physical activity to at least 150 minutes weekly. There will be weekly phone calls or texts (participants' choice) providing a total of 26 points of contact recommended by the United States Preventive Services Task Force.

Locations

Country	Name	City	State
United States	Emory University Hospital	Atlanta	Georgia
United States	Emory University Hospital Midtown	Atlanta	Georgia
United States	Grady Health System	Atlanta	Georgia
United States	The Emory Clinic	Atlanta	Georgia
United States	Emory Johns Creek Hospital	Johns Creek	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hemoglobin A1c	The hemoglobin A1c test result reflects average blood sugar level for the past two to three months. Specifically, the A1c test measures what percentage of hemoglobin is coated with sugar (glycated). The higher A1c level, the poorer blood sugar control and the higher risk of diabetes complications.	Baseline, Month 3, Month 6, Month 12
Primary	Insulin Resistance Score Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)	Insulin resistance score HOMA-IR is computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate high insulin sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin resistance).	Baseline, Month 3, Month 6, Month 12
Primary	Number of Deaths Among Recipients of the Cryoablation	Mortality among recipients of the cryoablation was documented.	Up to Month 12
Primary	Number of Adverse Events Related to the Cryoablation	The count of procedure related complications, such as bleeding, infection, pneumothorax, hemothorax, pulmonary injury, complications of sedation, pain requiring hospital admission or treatment, dysphagia, gastroparesis, nausea and vomiting, and gastrointestinal ulceration was documented for the duration of the study.	Up to Month 12
Secondary	Body Mass Index (BMI)	Body Mass Index (BMI) is a person's weight in kilograms divided by the square of height in meters.	Baseline, Month 3, Month 6
Secondary	Waist Circumference	Waist circumference is a measurement taken around the abdomen at the level of the umbilicus (belly button). Waist circumference is measured in centimeters.	Baseline, Month 3, Month 6
Secondary	Waist-to-hip Ratio	A waist-to-hip ratio of greater than 1.0 indicates a higher risk of developing heart disease. For women, a healthy waist-to-hip ratio is less than 0.85 while under 0.9 is a healthy ratio for men.	Baseline, Month 3, Month 6
Secondary	Total Cholesterol	A healthy level of total cholesterol is 125 - 200 mg/dL.	Baseline, Month 6
Secondary	Low-Density Lipoprotein (LDL)	A healthy level of LDL is less than 100 mg/dL.	Baseline, Month 6
Secondary	Triglycerides	A healthy level of triglycerides is less than 150 mg/dL.	Baseline, Month 6
Secondary	Systolic Blood Pressure	A normal systolic blood pressure level is less than 120 millimeters of mercury (mmHg).	Baseline, Month 3, Month 6
Secondary	Diastolic Blood Pressure	A normal diastolic blood pressure level is less than 80 mmHg.	Baseline, Month 3, Month 6
Secondary	Daily Caloric Intake	Daily caloric intake is measured by 3-day food recall. Mean daily caloric intake is assessed as kilocalories (kcal) consumed per day.	Baseline, Month 3, Month 6
Secondary	Change in Anti-hyperglycemic Medication Regimen	Anti-hyperglycemic medications will be adjusted at visits under the direction of the endocrinologist, or as needed for clinically significant hypo- or hyperglycemic events. Changes in baseline medication regimen will be examined to determine if medication needs decrease or increase during the study.	Month 3, Month 6
Secondary	Appetite Visual Analog Scale Score for Hunger	The Appetite Visual Analog Scale includes 8 items which are scored on 100-mm visual analogue scales. The item for hunger asks participants how hungry they feel, where 0 = not at all and 100 = never been more hungry.	Baseline, Week 1, Month 1, Month 3, Month 6
Secondary	Appetite Visual Analog Scale Score for Satisfaction	The Appetite Visual Analog Scale includes 8 items which are scored on 100-mm visual analogue scales. The item for satisfaction asks participants how satisfied they feel, where 0 = completely empty and 100 = cannot eat another bite.	Baseline, Week 1, Month 1, Month 3, Month 6
Secondary	Appetite Visual Analog Scale Score for Fullness	The Appetite Visual Analog Scale includes 8 items which are scored on 100-mm visual analogue scales. The item for fullness asks participants how full they feel, where 0 = not full at all and 100 = totally full.	Baseline, Week 1, Month 1, Month 3, Month 6
Secondary	Appetite Visual Analog Scale Score for Eating Quantity	The Appetite Visual Analog Scale includes 8 items which are scored on 100-mm visual analogue scales. The item for eating quantity asks participants how much they think they can eat, where 0 = nothing at all and 100 = a lot.	Baseline, Week 1, Month 1, Month 3, Month 6
Secondary	Appetite Visual Analog Scale Score for Desire for Certain Foods	The Appetite Visual Analog Scale includes 8 items which are scored on 100-mm visual analogue scales. Four items of the questionnaire ask participants if they would like to eat something sweet, salty, savory, and fatty. Each item is scored as 0 = yes, very much and 100 = no, not at all.	Baseline, Week 1, Month 1, Month 3, Month 6
Secondary	International Physical Activity Questionnaire (IPAQ) Score	The IPAQ assesses physical activity during the past 7 days with 27 items. Based on the type, duration, and frequency of activity, respondents are categorized as having low activity, moderate activity, or high activity.	Baseline, Month 3, Month 6
Secondary	Fasting Glucose Level	A normal fasting blood sugar level is 99 mg/dL or lower, glucose levels of 100 - 125 mg/dL indicates prediabetes, and levels of 126 mg/dL and higher indicates diabetes.	Baseline, Month 3, Month 6
Secondary	Fasting Insulin Level	A normal fasting insulin level for the Emory Healthcare Laboratory is 1.9 to 23.0 milli-international units per liter (mIU/L). High levels of fasting insulin are associated with obesity and early stage type 2 diabetes (T2D). Type 1 diabetes and advanced T2D are associated with low levels of insulin.	Baseline, Month 3, Month 6